CELC (Celcuity) Research & Development: $145.83 Mil (TTM As of Mar. 2026)


CELC Celcuity Inc CELC
26 GF Score
Price $96.38
! 2 Warning Signs
View Full Analysis

What is Celcuity Research & Development?

Celcuity CELC +6.95% 26 Research & Development is $145.83 Mil as of Mar. 2026. GuruFocus rates CELC with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Celcuity's Research & Development for the three months ended in Mar. 2026 was $33.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $145.83 Mil.

Celcuity  (NAS:CELC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Celcuity Research & Development Related Terms

Celcuity Research & Development Historical Data

* Premium members only.

The historical data trend for Celcuity's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity Research & Development Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.76 35.29 60.59 104.20 145.00

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.76 40.22 34.92 37.63 33.06
CELC
26GF Score
Celcuity Inc CELC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $145.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $145.83 Mil mean?
Celcuity (CELC) has a Research & Development of $145.83 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Celcuity and its competitors.
Is Celcuity's Research & Development too high?
Celcuity's current Research & Development is $145.83 Mil. Overall, Celcuity has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Research & Development compare to PTGX and SYRE?
Celcuity's Research & Development of $145.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Celcuity and its competitors. Celcuity's current Research & Development is $145.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (CELC) has a current Research & Development of $145.83 Mil. The current Research & Development is $145.83 Mil. Celcuity's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Celcuity (CELC), the current Research & Development is $145.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges 7VR:Germany
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
26GF Score

Get the complete analysis for CELC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$96.38
Price